A Second Look: Retrospective Identification of Thrombotic Microangiopathy in Pediatric Stem Cell Transplant Patients With Veno‐Occlusive Disease
Pediatric Transplantation · 2025
DOI: 10.1111/petr.70003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Transplantation, 2025. Verfasst von Mahvish Q Rahim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hematology Oncology and Stem Cell Transplant, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Veno‐occlusive disease (VOD) and transplant‐associated thrombotic microangiopathy (TA‐TMA) remain a diagnostic and therapeutic challenge for patients undergoing hematopoietic stem cell transplant (HSCT). Both VOD and TA‐TMA share an underlying etiology of microvascular endothelial damage. Potential under‐recognition of TA‐TMA in the context of VOD leaves HSCT recipients vulnerable to additional endothelial damage, and risk of end‐organ failure.
Methods
A cohort of 44 pediatric HSCT recipients diagnosed with VOD between 2010and 2019 were retrospectively evaluated for the development of TA‐TMA within 1 week before and 2 months after VOD diagnosis. Patients were classified into three categories: sole diagnosis of VOD (VOD), concurrent clinical diagnosis of TA‐TMA during the VOD course (VOD+TA‐TMA), and patients with VOD who on retrospective review satisfied criteria for diagnosis of TA‐TMA (VOD+rTA‐TMA).
Results
A total of 42 patients were evaluated and 50% of the patients were diagnosed clinically with TA‐TMA (5) or where retrospectively identified to have TA‐TMA (16). There was no difference in the severity of the course of VOD between the three groups based on need for intubation, dialysis, and pediatric intensive care unit (PICU) care. Patients in the VOD only group had the highest survival at 1 year (66.7%, n = 14) compared with patients in the VOD+TA‐TMA group (60%, n = 3) and VOD+rTA‐TMA group (62.5%, n = 10), p = 0.9582.
Conclusion
Better understanding of the association between these two endotheliopathies is essential to improve diagnosis, treatment, and prevention of potentially fatal adverse outcomes in transplant recipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pediatric Hematology Oncology and Stem Cell Transplant, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, USA.
- Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana, USA.
ORCID-Profile: Mahvish Q Rahim
Zitieren
APA
Rahim, M. Q., Nichols, C., Althouse, S., & Rahrig, A. L. (2025). A Second Look: Retrospective Identification of Thrombotic Microangiopathy in Pediatric Stem Cell Transplant Patients With Veno‐Occlusive Disease. Pediatric Transplantation. https://doi.org/10.1111/petr.70003
Vancouver
Rahim MQ, Nichols C, Althouse S, Rahrig AL. A Second Look: Retrospective Identification of Thrombotic Microangiopathy in Pediatric Stem Cell Transplant Patients With Veno‐Occlusive Disease. Pediatric Transplantation. 2025. doi:10.1111/petr.70003
BibTeX
@article{Rahim2025,
author = {Rahim, Mahvish Q and Nichols, Cydney and Althouse, Sandra and Rahrig, April L},
title = {A Second Look: Retrospective Identification of Thrombotic Microangiopathy in Pediatric Stem Cell Transplant Patients With Veno‐Occlusive Disease},
journal = {Pediatric Transplantation},
year = {2025},
doi = {10.1111/petr.70003}
}
EUVIMED